Xadago is intended to be used as an add-on treatment for patients with Parkinson’s disease who are already taking a combination therapy of levodopa and carbidopa for the condition, yet still experiencing “off” episodes.
“Off episodes” occur when a patient’s medication is not working properly, resulting in heightened Parkinson’s symptoms like tremors or difficulty walking, according to the FDA.
“Xadago as an add-on to levodopa/carbidopa provided a significant reduction in off time and a significant increase in ON time without troublesome dyskinesia in [Parkinson’s] patients experiencing motor fluctuations,” Warren Olanow, MD, a professor of neurology and neuroscience at the Mount Sinai School of Medicine in New York City, said in a statement.
More articles on supply chain:
96% of older Americans want Medicare to negotiate drug costs: 4 survey findings
FDA granted 99% of applications for access to unapproved drugs in FY 2016
FDA warns of safety risks with Abbott’s dissolving stent: 5 takeaways
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
